By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% ...
The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...
Pfizer (PFE +0.85%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for ...
Pfizer is looking to newer products and acquisitions to offset a declining Covid business.
House Republicans subpoenaed Pfizer’s former Vice President and Chief Scientific Officer of RNA and Viral Vaccines Dr. Philip Dormitzer. The House Judiciary Committee requested in May that Dormitzer ...
Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.
A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...
(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI ® (marstacimab) to include patients 12 years of age and ...
Pfizer has been working on ways to expand its growth prospects, as it faces even more challenges ahead as key products lose ...
May 12 (Reuters) - Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product ...
Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results